Offer - Urjas Oil for just ₹ 1
Eurythmic is a commercial drug that is prescribed in the form of Tablet, Injection. It is typically used for the treatment of Arrhythmia. Secondary and off-label uses of Eurythmic have also been mentioned below.
Medical history of the patient along with age and gender determines the dosage of Eurythmic. Individual symptoms and route of administration also determines the right dosage. Detailed information has been provided in the dosage section.
Common side effects of Eurythmic include Shortness of Breath, Cough, Trembling. Some other side effects of Eurythmic have been listed ahead. Normally, these side effects of Eurythmic are not long lasting and go away when the treatment is finished. Consult your doctor if these side effects become worse or stay for a longer duration.
Eurythmic's effect during pregnancy is Severe and Severe while nursing. In addition, Eurythmic's effects on the liver, heart and kidney are discussed below in the Eurythmic related warnings section.
Individuals suffering from medical conditions like Heart Failure, Heart Disease must refrain from the use of Eurythmic since this can cause severe adverse effects. Some other conditions that can be affected by Eurythmic are listed in the contraindications section below.
Drug reaction of Eurythmic with other medicines has been reported. A complete list of these interactions is given below.
Along with the above-mentioned precautions, remember that taking Eurythmic is considered not safe while driving, and is not addictive.
Eurythmic is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
| 13 - 18 years (Adolescent) |
|
| 2 - 12 years (Child) |
|
| Infant (1 month to 2 years) |
|
| Neonates (0 to 1 month) |
|
Is the use of Eurythmic safe for pregnant women?
Eurythmic should not be taken during pregnancy, or should only be taken on the advice of a doctor as it may have severe side effects.
Is the use of Eurythmic safe during breastfeeding?
Eurythmic may cause serious side effects in breastfeeding women, so do not take this drug without doctor's advice.
What is the effect of Eurythmic on the Kidneys?
Eurythmic is not harmful for kidneys.
What is the effect of Eurythmic on the Liver?
There are no any side effects of Eurythmic on the liver.
What is the effect of Eurythmic on the Heart?
Very few cases of side effects of Eurythmic on the heart have been reported.
Eurythmic should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
If you are suffering from any of the following diseases, you should not take Eurythmic unless your doctor advises you to do so -
Is this Eurythmic habit forming or addictive?
No, there is no any evidence that Eurythmic is addictive.
Is it safe to drive or operate heavy machinery when consuming?
You may feel sleepy or tired after taking Eurythmic. So it is best to avoid driving.
Is it safe?
Yes, but take Eurythmic only as per medical advice.
Is it able to treat mental disorders?
No, Eurythmic cannot treat any kind of mental disorder.
Interaction between Food and Eurythmic
Taking certain foods and Eurythmic together may have severe side effects. Talk to your doctor about it.
Interaction between Alcohol and Eurythmic
Due to lack of research, nothing can be said about side effects of consuming alcohol while taking Eurythmic.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Cordarone® (amiodarone HCl)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 533-534
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 141-144
